SynthesisFrontiers in cellular and infection microbiology2026
Targeting TRPV1 channels: new perspectives on the mechanisms of analgesia for herpes zoster neuralgia and advances in therapeutic research.
Synthesis in Frontiers in cellular and infection microbiology, 2026. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
0 citing papers in PubMed.
No citing paper in PubMed yet.
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
4 authors.
Funding
No grant is acknowledged in the PubMed record.
Abstract
Herpes Zoster Neuralgia (HZN) is a condition caused by the varicella-zoster virus, characterized primarily by pain. The Transient Receptor Potential Vanilloid 1 (TRPV1), which acts as a pain mediator, plays a significant role in pain signaling and the regulation of neuroinflammation. In this context, this paper summarizes the biological characteristics of TRPV1, its dynamic expression in HZN, and its mechanisms for mediating neuroinflammatory processes and pain signal conduction. It posits that the inhibition of TRPV1 may alleviate HZN. Furthermore, the paper discusses the research and development progress, as well as the challenges associated with TRPV1 antagonists as a new class of analgesics, thereby providing new insights for the treatment of HZN.
Indexed as
Identifiers
What Socratic holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the Socratic graph.